ASCO Plenary Study: Sorafenib Extends Progression-Free Survival Time for Patients with Resistant Differentiated Thyroid Cancer


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles